S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)

AbbVie (ABBV) Price Target & Analyst Ratings

$153.13
-0.78 (-0.51%)
(As of 05:18 PM ET)
Compare
Today's Range
$151.61
$154.00
50-Day Range
$137.68
$154.70
52-Week Range
$130.96
$168.11
Volume
3.59 million shs
Average Volume
5.59 million shs
Market Capitalization
$270.28 billion
P/E Ratio
31.51
Dividend Yield
3.87%
Price Target
$165.79

AbbVie Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 15 Analyst Ratings

Consensus Analyst Price Target

$165.79
8.26% Upside
High Prediction$195.00
Average Prediction$165.79
Low Prediction$140.00
TypeCurrent
9/27/22 to 9/27/23
1 Month Ago
8/28/22 to 8/28/23
3 Months Ago
6/29/22 to 6/29/23
1 Year Ago
9/27/21 to 9/27/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
9 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$165.79$165.79$163.40$159.35
Predicted Upside8.26% Upside10.79% Upside8.82% Upside11.32% Upside
Get AbbVie Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.


ABBV Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AbbVie Stock vs. The Competition

TypeAbbVieMedical CompaniesS&P 500
Consensus Rating Score
2.47
2.66
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside7.72% Upside1,375.06% Upside697.64% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/28/2023Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$163.00 ➝ $170.00+12.63%
7/28/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$163.00 ➝ $170.00+13.68%
7/25/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$167.00+25.04%
7/12/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$170.00 ➝ $160.00+18.02%
4/28/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$172.00 ➝ $171.00+14.87%
4/28/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$200.00 ➝ $195.00+30.99%
4/12/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$155.00 ➝ $160.00-0.86%
4/10/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$178.00 ➝ $181.00+12.04%
4/5/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
2/22/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
2/10/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$157.00 ➝ $154.00+1.83%
2/10/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00+2.89%
2/10/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00+2.89%
2/6/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$169.00 ➝ $167.00+15.01%
1/5/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$160.00 ➝ $180.00+10.00%
11/8/2022Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$155.00 ➝ $140.00-7.32%
(Data available from 9/27/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ABBV Price Target - Frequently Asked Questions

What is AbbVie's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for AbbVie stock is Hold based on the current 8 hold ratings and 7 buy ratings for ABBV. The average twelve-month price prediction for AbbVie is $165.79 with a high price target of $195.00 and a low price target of $140.00. Learn more on ABBV's analyst rating history.

Do Wall Street analysts like AbbVie more than its competitors?

Analysts like AbbVie less than other Medical companies. The consensus rating for AbbVie is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how ABBV compares to other companies.

Does AbbVie's stock price have much upside?

According to analysts, AbbVie's stock has a predicted upside of 10.79% based on their 12-month price targets.

What analysts cover AbbVie?

AbbVie has been rated by Credit Suisse Group, HSBC, Piper Jaffray Companies, Piper Sandler, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:ABBV) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -